Phase I/II study of Resiquimod as an immunologic adjuvant for NY-ESO-1 protein vaccination in patients with melanoma
Year: 2013
Type: article
Study design: Clinical Trial
Abstract: Meeting abstracts The TLR 7/8 agonist, Resiquimod has been shown to induce local activation of immune cells, production of cytokines, and antigen-presentation by dendritic cells, features desirable for cancer vaccine adjuvants. In this study, we evaluated the safety and immunogenicity of
Authors: Rachel L Sabado, Anna Pavlick, Sacha Gnjatic, Crystal Cruz, Isabelita Vengco, Farah Hasan, Farbod Darvishian, Luis Chiriboga, Rose Marie Holman, Juliet Escalon, Caroline Muren, Crystal Escano, Ethel Yepes, Dunbar Sharpe, Sylvia Adams, Patrick Ott, Achim Jungbluth, Linda Pan, Ralph Venhaus, Nina Bhardwaj
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
Estimated APC paid: $2,490
OpenAlex ID: W2092530164